| |
| Issue |
Title |
| |
| No 16 (2021) |
Assessment of life quality indicators and the role of commitment in achieving control in severe bronchial asthma |
Abstract
PDF (Rus)
|
|
E. A. Sobko, I. V. Demko, A. Yu. Kraposhina, N. V. Gordeeva, O. P. Ischenko, S. A. Egorov, D. N. Okulova, N. S. Smolnikov, A. I. Avdeeva |
| |
| No 16 (2021) |
Combined therapy with inhaled glucocorticosteroids and long-acting β2-agonists in patients with bronchial asthma: the problem of choice |
Abstract
PDF (Rus)
|
|
A. I. Sinopalnikov |
| |
| No 16 (2021) |
Increased treatment adherence in patients with chronic obstructive pulmonary disease when using a fixed triple combination |
Abstract
PDF (Rus)
|
|
E. V. Bolotova, A. V. Dudnikova, L. V. Shulzhenko |
| |
| No 16 (2021) |
Omalizumab and modification of bronchial asthma natural course |
Abstract
PDF (Rus)
|
|
N. P. Kniajeskaia, E. H. Anaev, A. S. Belevskiy, A. A. Kameleva, E. V. Safoshkina, N. D. Kirichenko |
| |
| No 16 (2021) |
Clinical experience of using formoterol/budesonide in patients with chronic obstructive pulmonary disease |
Abstract
PDF (Rus)
|
|
I. V. Demko, M. G. Mamaeva, E. A. Sobko, A. Yu. Kraposhina, N. V. Gordeeva |
| |
| No 16 (2021) |
Respimat as the new standard for inhalation therapy devices |
Abstract
PDF (Rus)
|
|
V. V. Arkhipov |
| |
| No 16 (2021) |
Pharmacotherapeutic strategy for COPD patients: focus on dual bronchodilators |
Abstract
PDF (Rus)
|
|
A. I. Sinopalnikov |
| |
| 1 - 7 of 7 Items |
|
